Merit Medical Stock Remains a Hold as Strong Q1 Results Support Portfolio Confidence
Merit Medical Stock Remains a Hold as Strong Q1 Results Support Portfolio Confidence
Merit Medical Systems, Inc. (NASDAQ: MMSI) continues to attract investor attention after analysts highlighted several reasons to retain the medical device stock in portfolios. The company’s recent performance shows steady revenue growth, stronger earnings, and a positive full-year outlook, even as foreign exchange pressure and broader macroeconomic risks remain concerns.
Strong First-Quarter Results Strengthen Investor Confidence
Merit Medical reported first-quarter 2026 revenue of $381.9 million, representing a 7% increase from the prior-year period. The company also posted GAAP earnings per share of $0.68, up 39%, while non-GAAP earnings per share reached $0.94, rising 9% year over year. These results suggest that Merit Medical is maintaining healthy demand across its product categories and geographic markets.
The company’s operating performance also remained stable. GAAP operating margin improved slightly to 11.6%, compared with 11.5% a year earlier. Non-GAAP operating margin increased to 19.7%, compared with 19.3% in the prior-year quarter. This shows that management is keeping a close eye on cost control while continuing to invest in growth areas.
Product Portfolio Remains a Key Growth Driver
Merit Medical designs and manufactures disposable medical devices used in interventional, diagnostic, and therapeutic procedures. Its portfolio covers areas such as cardiology, radiology, oncology, critical care, endoscopy, peripheral intervention, dialysis access, spine, and embolotherapy. This wide product base helps reduce dependence on one single category and gives the company several ways to grow.
The company’s product diversity is important because hospitals and physicians continue to seek minimally invasive tools that can improve patient care, shorten procedure times, and support better clinical outcomes. Merit Medical’s focus on specialized devices gives it a useful position in a healthcare market that values both innovation and reliability.
Updated 2026 Guidance Adds Support
For full-year 2026, Merit Medical expects total revenue between $1.612 billion and $1.634 billion, implying annual growth of about 6% to 8%. The company also expects non-GAAP earnings per share between $4.01 and $4.15. Management said the updated outlook includes the impact of the View Point Medical acquisition.
This guidance suggests that Merit Medical expects steady demand to continue through the year. While the growth rate is not explosive, it appears consistent and supported by both organic business activity and acquisitions. For long-term investors, that type of steady execution can be valuable, especially in the medical device industry.
Acquisitions Could Expand Future Opportunities
Merit Medical has used acquisitions to strengthen its portfolio and enter attractive medical technology niches. The View Point Medical deal, announced in 2026, is expected to add a small amount of revenue during the year, while near-term earnings may face some dilution due to transaction-related effects. Even so, the acquisition can support Merit Medical’s longer-term oncology strategy.
Earlier portfolio expansion efforts also show that the company is willing to use capital to build scale. For example, Merit Medical previously expanded in dialysis and biopsy-related products through transactions involving catheter and biopsy tract sealant assets. These types of moves can help the company add revenue streams while deepening relationships with hospitals and clinicians.
Risks Still Need Attention
Despite the positive outlook, investors should not ignore risks. Currency volatility may affect reported sales because Merit Medical operates globally. Inflation, hospital budget pressure, supply-chain issues, and regulatory requirements can also influence profitability. In addition, medical device companies must keep investing in research and development to remain competitive.
Valuation is another factor to watch. A strong business does not automatically make a stock cheap. Investors should compare Merit Medical’s growth rate, margins, earnings outlook, and debt position with other medical device companies before making decisions.
Why Analysts Suggest Retaining the Stock
The case for holding Merit Medical stock is based on several points: steady revenue growth, improving earnings, a broad product portfolio, disciplined cost control, and a full-year outlook that remains constructive. The company is not without challenges, but its latest results show operational strength.
For investors already holding MMSI shares, the current picture supports patience rather than a quick exit. Merit Medical appears well positioned in important medical device markets, and its product strategy gives it room to grow over time. However, new investors may want to study valuation and market conditions carefully before entering.
Conclusion
Merit Medical stock remains a portfolio candidate for investors seeking exposure to the medical device sector. The company’s first-quarter results, updated 2026 guidance, and broad medical technology portfolio support the argument for retaining the stock. Still, investors should balance the positives against currency pressure, macroeconomic uncertainty, and valuation risk.
Overall, Merit Medical’s latest performance shows a company with steady execution, useful healthcare products, and a clear focus on long-term growth.
#MeritMedical #MMSI #MedicalDevices #StockMarket #SlimScan #GrowthStocks #CANSLIM